Contact
searchSearch
HMP Global
Login

Interactive Features

Quiz
Tocilizumab Plus Gemcitabine and Nab-Paclitaxel for Patients With Advanced Pancreatic Cancer
09/23/2025
In the phase 2 PATCO trial assessing the addition of tocilizumab to gemcitabine plus nab-paclitaxel among patients with advanced pancreatic cancer, which statement best reflects the implications for clinical practice?
In the phase 2 PATCO trial assessing the addition of tocilizumab to gemcitabine plus nab-paclitaxel among patients with advanced pancreatic cancer, which statement best reflects the implications for clinical practice?
In the phase 2 PATCO trial...
09/23/2025
Oncology
Quiz
Quiz: Is FOLFIRINOX a Superior Treatment for Patients With Resectable Pancreatic Cancer?
09/08/2021
True or false: Results from the SWOG 1505 trial indicate that FOLFIRINOX was a superior therapy choice compared with gemcitabine plus nab-paclitaxel in patients with resectable pancreatic cancer.
True or false: Results from the SWOG 1505 trial indicate that FOLFIRINOX was a superior therapy choice compared with gemcitabine plus nab-paclitaxel in patients with resectable pancreatic cancer.
True or false: Results from the...
09/08/2021
Oncology
Quiz
Quiz: Is FOLFIRINOX a Superior Treatment for Patients With Resectable Pancreatic Cancer?
09/08/2021
True or false: Results from the SWOG 1505 trial indicate that FOLFIRINOX was a superior therapy choice compared with gemcitabine plus nab-paclitaxel in patients with resectable pancreatic cancer.
True or false: Results from the SWOG 1505 trial indicate that FOLFIRINOX was a superior therapy choice compared with gemcitabine plus nab-paclitaxel in patients with resectable pancreatic cancer.
True or false: Results from the...
09/08/2021
Oncology
Quiz
Quiz: Do Molecularly-Matched Therapies Improve OS for Pancreatic Cancer?
08/12/2021
Molecularly-matched treatments for patients with pancreatic cancer significantly increase overall survival.
Molecularly-matched treatments for patients with pancreatic cancer significantly increase overall survival.
Molecularly-matched treatments...
08/12/2021
Oncology
Quiz
Quiz: What is the Median Age of Patients Diagnosed with Pancreatic Cancer?
08/03/2021
True or False: The median age of patients who are diagnosed with pancreatic cancer is 70 years old.
True or False: The median age of patients who are diagnosed with pancreatic cancer is 70 years old.
True or False: The median age of...
08/03/2021
Oncology
Test Your Knowledge
Quiz: Which Combination Benefits Patients with Mesothelin-Expressing Solid Tumors?
08/06/2020
Which combination yielded manageable safety and encouraging antitumor activity in patients with mesothelin-expressing solid tumors?
Which combination yielded manageable safety and encouraging antitumor activity in patients with mesothelin-expressing solid tumors?
Which combination yielded...
08/06/2020
Oncology
Test Your Knowledge
Quiz: Adjuvant Chemoradiation for High-Risk Pancreatic Cancer
09/26/2019
True or False: Adding radiation to adjuvant chemotherapy has been shown to encourage a clinically small but meaningful increase in survival.
True or False: Adding radiation to adjuvant chemotherapy has been shown to encourage a clinically small but meaningful increase in survival.
True or False: Adding radiation...
09/26/2019
Oncology
Test Your Knowledge
Quiz: Durvalumab Combo Therapy for Pancreatic Cancer
08/27/2019
Durvalumab therapy plus _______ was well-tolerated but demonstrated poor activity in a study of patients with metastatic pancreatic ductal adenocarcinoma.
Durvalumab therapy plus _______ was well-tolerated but demonstrated poor activity in a study of patients with metastatic pancreatic ductal adenocarcinoma.
Durvalumab therapy plus _______...
08/27/2019
Oncology
Test Your Knowledge
Quiz: Can Hydroxychloroquine Improve OS in Patients With Pancreatic Cancer?
07/09/2019
True or false: In a recent study, adding hydroxychloroquine to chemotherapy improved overall survival in patients with metastatic pancreatic cancer.
True or false: In a recent study, adding hydroxychloroquine to chemotherapy improved overall survival in patients with metastatic pancreatic cancer.
True or false: In a recent...
07/09/2019
Oncology
Test Your Knowledge
Quiz: FOLFIRINOX Outshines Gemcitabine in Pancreatic Cancer
04/17/2019
True or false: Six months of postoperative treatment with the combination of fluorouracil, leucovorin, irinotecan and oxaliplatin (ie, FOLFIRINOX) improved survival rates over conventional gemcitabine therapy in a recent study of patients...
True or false: Six months of postoperative treatment with the combination of fluorouracil, leucovorin, irinotecan and oxaliplatin (ie, FOLFIRINOX) improved survival rates over conventional gemcitabine therapy in a recent study of patients...
True or false: Six months of...
04/17/2019
Oncology

Recent News

News
Genotype-Guided Therapy Demonstrates High Response and Survival Rates for Patients With R/R DLBCL
09/26/2025
Emily Estrada
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE...
09/26/2025
Oncology
News
PD-1/PD-L1 Inhibitor Monotherapy Demonstrates Accceptable Safety, Limited Efficacy for R/R DLBCL
09/26/2025
Emily Estrada
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large...
09/26/2025
Oncology
News
Polatuzumab-Based Regimens Demonstrate Promising Efficacy for R/R DLBCL Compared to Traditional Salvage Therapies
09/26/2025
Emily Estrada
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional...
09/26/2025
Oncology
FDA Approval
FDA Approves Imlunestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
09/25/2025
Stephanie Holland
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved...
09/25/2025
Oncology
News
Pexidartinib Shows Durable Response Among Patients with Tenosynovial Giant Cell Tumors
09/25/2025
Allison Casey
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained...
09/25/2025
Oncology
News
Clarithromycin-Based Quadruplet Therapy Demonstrates Promising Clinical Responses for Treatment of Relapsed/Refractory Multiple Myeloma
09/24/2025
Emily Estrada
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with...
09/24/2025
Oncology
News
First-Line mFOLFIRINOX, S-IROX Fail to Improve Survival Among Patients With Recurrent or Metastatic Pancreatic Cancer
09/23/2025
Stephanie Holland
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3...
09/23/2025
Oncology
News
Novel Anti-CSF1 Receptor Antibody for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial,...
09/23/2025
Oncology
News
Adverse Events With Pexidartinib for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the...
09/23/2025
Oncology
News
Trifluridine/Tipiracil Plus Bevacizumab Escalation Demonstrates Promise Among Patients With Advanced or Unresectable Metastatic Colorectal Cancer
09/22/2025
Stephanie Holland
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the...
09/22/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use